Literature DB >> 10464273

Inflammatory cytokine regulation of Fas-mediated apoptosis in thyroid follicular cells.

J D Bretz1, P L Arscott, A Myc, J R Baker.   

Abstract

The occurrence of apoptosis in thyroid follicular cells induced by Fas activation has been a subject of much debate. This is due, in part, to the fact that no physiologically relevant treatment conditions have been reported to cause rapid and extensive Fas-mediated apoptosis in thyroid cells, whereas treatment with the protein synthesis inhibitor cycloheximide prior to Fas activation allows for massive cell death. This indicates that the Fas signaling pathway is present but that its function is blocked in the overwhelming majority of cultured thyroid cells. To reconcile the conflicting reports, we set out to identify physiologically relevant conditions in which rapid, massive thyroid cell apoptosis in response to Fas activation could be demonstrated. We determined that susceptibility to Fas-activated apoptosis could be influenced by certain combinations of inflammatory cytokines. Although no single cytokine was effective, pretreatment of thyroid cells with the combination of gamma-interferon and either tumor necrosis factor-alpha or interleukin 1beta allowed for massive Fas-mediated apoptosis. Susceptibility to Fas-induced death correlated with an increase in expression of a tunicamycin-inhibitable high molecular weight form of Fas but not with aggregate expression of Fas.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10464273     DOI: 10.1074/jbc.274.36.25433

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  14 in total

Review 1.  The role of apoptosis in autoimmune thyroid disorders and thyroid cancer.

Authors:  J D Lin
Journal:  BMJ       Date:  2001-06-23

Review 2.  Effector lymphocytes in islet cell autoimmunity.

Authors:  Pere Santamaria
Journal:  Rev Endocr Metab Disord       Date:  2003-09       Impact factor: 6.514

3.  IL-1alpha, IL-1beta, and IFN-gamma mark beta cells for Fas-dependent destruction by diabetogenic CD4(+) T lymphocytes.

Authors:  A Amrani; J Verdaguer; S Thiessen; S Bou; P Santamaria
Journal:  J Clin Invest       Date:  2000-02       Impact factor: 14.808

4.  Alpha-fodrin as a putative autoantigen in Graves' ophthalmopathy.

Authors:  G J Kahaly; H Bang; W Berg; M Dittmar
Journal:  Clin Exp Immunol       Date:  2005-04       Impact factor: 4.330

5.  Murine FLIP transgene expressed on thyroid epithelial cells promotes resolution of granulomatous experimental autoimmune thyroiditis in DBA/1 mice.

Authors:  Yujiang Fang; Yongzhong Wei; Vincent Demarco; Kemin Chen; Gordon C Sharp; Helen Braley-Mullen
Journal:  Am J Pathol       Date:  2007-03       Impact factor: 4.307

6.  Regulation of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in thyroid carcinoma cells.

Authors:  Vassiliki Poulaki; Constantine S Mitsiades; Vassiliki Kotoula; Sophia Tseleni-Balafouta; Avi Ashkenazi; Demetrios A Koutras; Nicholas Mitsiades
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

7.  A critical role for TRAIL in resolution of granulomatous experimental autoimmune thyroiditis.

Authors:  Y Fang; G C Sharp; H Yagita; H Braley-Mullen
Journal:  J Pathol       Date:  2008-12       Impact factor: 7.996

8.  Cultured murine thyroid epithelial cells expressing transgenic Fas-associated death domain-like interleukin-1beta converting enzyme inhibitory protein are protected from fas-mediated apoptosis.

Authors:  Yujiang Fang; Helen Braley-Mullen
Journal:  Endocrinology       Date:  2008-03-20       Impact factor: 4.736

9.  Interleukin-10 promotes resolution of granulomatous experimental autoimmune thyroiditis.

Authors:  Yujiang Fang; Gordon C Sharp; Helen Braley-Mullen
Journal:  Am J Pathol       Date:  2008-05-08       Impact factor: 4.307

Review 10.  Unravelling the genetic complexity of autoimmune thyroid disease: HLA, CTLA-4 and beyond.

Authors:  M J Simmonds; S C L Gough
Journal:  Clin Exp Immunol       Date:  2004-04       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.